OrthoPediatrics (NASDAQ:KIDS – Get Free Report) is expected to announce its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect OrthoPediatrics to post earnings of ($0.31) per share and revenue of $68.21 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.04. OrthoPediatrics had a negative net margin of 16.31% and a negative return on equity of 7.01%. The business had revenue of $59.36 million during the quarter, compared to analyst estimates of $58.28 million. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
OrthoPediatrics Stock Performance
KIDS stock traded up $0.07 during midday trading on Tuesday, reaching $19.89. 24,716 shares of the company’s stock traded hands, compared to its average volume of 157,204. The firm has a market capitalization of $510.78 million, a PE ratio of -11.84 and a beta of 0.99. The company has a 50-day moving average price of $18.84 and a two-hundred day moving average price of $17.75. OrthoPediatrics has a 52 week low of $14.42 and a 52 week high of $22.89. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.37 and a current ratio of 5.21.
Institutional Investors Weigh In On OrthoPediatrics
Wall Street Analysts Forecast Growth
KIDS has been the subject of several recent research reports. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Canaccord Genuity Group set a $25.00 target price on OrthoPediatrics in a research note on Friday, April 24th. BTIG Research reaffirmed a “buy” rating and set a $24.00 target price on shares of OrthoPediatrics in a report on Friday, May 1st. Truist Financial upped their price target on OrthoPediatrics from $17.00 to $20.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a report on Friday, July 17th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.78.
Get Our Latest Stock Report on KIDS
OrthoPediatrics Company Profile
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Recommended Stories
- Five stocks we like better than OrthoPediatrics
- Amkor Sells Off After Earnings—Why Weak Guidance Isn’t the Real Story
- 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys?
- Whirlpool’s Report May Show How Frozen the Housing Market Really Is
- 3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
